Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042990 | 0.91 | GPR119 (0.42) | GPR119NR1H2SQOR | |
| SCHEMBL4043737 | 0.86 | NR1H2 (0.39) | GPR119NR1H2CSNK1ECSNK1D | |
| SCHEMBL4039078 | 0.86 | CSNK1E (0.46) | GPR119NR1H2CSNK1EJAK2JAK1 | |
| SCHEMBL4039352 | 0.84 | SQOR (0.41) | GPR119NR1H2CSNK1EJAK2JAK1 | |
| SCHEMBL4038604 | 0.81 | CSNK1E (0.46) | NR1H2CSNK1ECSNK1D | |
| SCHEMBL4038225 | 0.79 | GPR119 (0.46) | GPR119NR1H2 | |
| SCHEMBL4039386 | 0.78 | GPR119 (0.45) | GPR119NR1H2 | |
| SCHEMBL4037481 | 0.77 | GPR119 (0.40) | GPR119NR1H2 | |
| SCHEMBL4041480 | 0.76 | GBA1 (0.49) | GPR119NR1H2CSNK1ECSNK1D | |
| SCHEMBL4045206 | 0.75 | CSNK1E (0.47) | GPR119NR1H2CSNK1ECSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950911-A1 | AUTOMATIC DISHWASHING METHOD | The Procter & Gamble Company (US) | 2022-02-09 | — | — | EP | claimed |
| EP-4488351-A1 | COMPOSITIONS CONTAINING A PORPHYRIN BINDING PROTEIN | The Procter & Gamble Company (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-4481027-A1 | CLEANING COMPOSITIONS CONTAINING ENZYMES | The Procter & Gamble Company (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-3485010-B1 | BACILLUS CIBI DNASE VARIANTS AND USES THEREOF | PROCTER & GAMBLE (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-4410941-A1 | DETERGENT COMPOSITIONS CONTAINING ENZYMES | The Procter & Gamble Company (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4276179-A2 | ALPHA-AMYLASE VARIANTS | Novozymes A/S (DK) | 2023-11-15 | — | — | EP | disclosed |
| EP-4273210-A1 | DETERGENT COMPOSITIONS CONTAINING ENZYMES | The Procter & Gamble Company (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3121270-B1 | CLEANING COMPOSITIONS COMPRISING AMYLASE VARIANTS REFERENCE TO A SEQUENCE LISTING | PROCTER & GAMBLE (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3357994-B1 | CLEANING COMPOSITIONS COMPRISING AMYLASE VARIANTS | PROCTER & GAMBLE (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230340378-A1 | DETERGENT COMPOSITIONS CONTAINING ENZYMES | THE PROCTER & GAMBLE COMPANY | 2023-10-26 | — | — | US | disclosed |
| EP-2540824-A1 | Cleaning compositions comprising amylase variants reference to a sequence listing | The Procter & Gamble Company (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-1828364-B1 | A COMPOSITION WITH A METAL-COMPLEXING DYE AND SURFACTANT | PROCTER & GAMBLE (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| EP-2010504-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007119055-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
| EP-1436291-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | Aventis Pharma S.A. (FR) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | GPR119 770/4885NR1H2 398/4885CSNK1E 136/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | GPR119 631/4885NR1H2 322/4885CSNK1E 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.